Publications

Poster presented at the AcademyHealth National Health Policy Conference in 2020, sharing findings from a program designed to enhance affordable housing for older adults

In this annual report for 2019, the HPC presents new research to enhance the collective understanding of health care spending trends and cost drivers and evaluates progress in meeting the Commonwealth’s cost containment, care delivery, and payment system goals.

The Office of Patient Protection (OPP), operated by the HPC, is responsible for regulating and administering certain health care consumer protections for the Commonwealth. OPP is a resource for individuals who want to become more informed and empowered health care consumers. This annual report provides a comprehensive overview of the activities of the Office in the year 2018.

These profiles provide a high-level snapshot of CHART Investment Program awardees, the care models they implemented, and the goals of their initiatives.

An annual report released by the HPC documenting projects and activities undertaken during the HPC's 2019 remote Summer Fellowship Program.

Emerging innovations and promising outcomes from an HPC investment program

This factsheet provides a high-level overview of the services provided by the HPC's Office of Patient Protection.

This DataPoints issue presents Massachusetts data from FAIR Health, Inc. on several specific services often involved in “surprise billing” scenarios and shows how payments would vary under different out-of-network payment benchmarks.

This brief provides an overview of the Community Hospital Acceleration, Revitalization, and Transformation (CHART) Program’s impact on building capacity, engaging patients, and transforming care in community hospital settings across Massachusetts.

This legislatively-mandated report examines the prevalence and impact of health insurance payer policies that seek to reduce overall pharmaceutical spending by requiring alternative methods of distribution and payment for certain costly specialty drugs. The clinician-administered drugs subject to these policies, administered not by a retail pharmacy but by a clinician to a patient through injection or infusion in the outpatient setting, are typically high priced and represent a growing share of all pharmaceutical spending.